말라리아 진단 시장 보고서 : 기술별, 최종 용도별, 지역별(2024-2032년)

The global malaria diagnostics market size reached US$ 829.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,383.3 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.

Malaria diagnostics refers to the clinical tests conducted to detect the presence of the infection in individuals. Malaria is caused by the bite of an infected female Anopheles mosquito, which leads to the transfer of Plasmodium parasites into the body. Some common symptoms include fever, fatigue, nausea and headaches. The infection is diagnosed through various rapid diagnostics, microscopy and molecular diagnostic tests. These tests use antigen detection and serology techniques using indirect immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA). They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.

Malaria Diagnostics Market Trends:

The increasing prevalence of malaria across the globe is one of the key factors creating a positive outlook for the market. Malaria is a life-threatening infection that has caused a significant loss of human lives, especially in developing nations. However, rising awareness among the masses regarding the available diagnostic and treatment alternatives for malaria is providing a thrust to the market growth. Healthcare centers and diagnostic laboratories are widely adopting microscopic diagnostics to identify the parasite at different stages and design suitable treatment plans. Additionally, various technological advancements, such as the development of the Quantitative Buffy Coat (QBC) method and peripheral blood smear technique for diagnosing malaria, are acting as other growth-inducing factors. In line with this, the availability of Point-of-Care (POC) diagnostic devices for enhanced accuracy is also contributing to the growth of the market. Other factors, including rising healthcare expenditure capacities of the masses, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global malaria diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technology and end use.

Breakup by Technology:

Microscopy

Rapid Diagnostic Tests (RDTs)

Molecular Diagnostic Tests

Conventional PCR

Real-Time PCR (qPCR)

Breakup by End Use:

Hospital

Clinics

Diagnostic Centers

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Access Bio, Beckman Coulter Inc. (Danaher Corporation), bioMerieux SA (Compagnie Merieux Alliance), Bio-Rad Laboratories Inc., Nikon Corporation, Novartis AG, Olympus Corporation, Premier Medical Corporation Pvt. Ltd., Siemens Healthcare GmbH (Siemens AG), Sysmex Corporation and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1. How big is the global malaria diagnostics market?
• 2. What is the expected growth rate of the global malaria diagnostics market during 2024-2032?
• 3. What are the key factors driving the global malaria diagnostics market?
• 4. What has been the impact of COVID-19 on the global malaria diagnostics market?
• 5. What is the breakup of the global malaria diagnostics market based on the technology?
• 6. What is the breakup of the global malaria diagnostics market based on the end use?
• 7. What are the key regions in the global malaria diagnostics market?
• 8. Who are the key players/companies in the global malaria diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Malaria Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Technology

• 6.1 Microscopy
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Rapid Diagnostic Tests (RDTs)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Molecular Diagnostic Tests
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Conventional PCR
    • 6.3.2.2 Real-Time PCR (qPCR)
  • 6.3.3 Market Forecast

7 Market Breakup by End Use

• 7.1 Hospital
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Clinics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Diagnostic Centers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Access Bio
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
  • 13.3.3 Beckman Coulter Inc. (Danaher Corporation)
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 SWOT Analysis
  • 13.3.4 bioMerieux SA (Compagnie Merieux Alliance)
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Bio-Rad Laboratories Inc.
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 Nikon Corporation
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Novartis AG
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Olympus Corporation
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Premier Medical Corporation Pvt. Ltd.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
  • 13.3.10 Siemens Healthcare GmbH (Siemens AG)
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Sysmex Corporation
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials
    • 13.3.11.4 SWOT Analysis
  • 13.3.12 Thermo Fisher Scientific Inc
    • 13.3.12.1 Company Overview
    • 13.3.12.2 Product Portfolio
    • 13.3.12.3 Financials
    • 13.3.12.4 SWOT Analysis